Human Journals

Research Article

December 2020 Vol.:20, Issue:1

© All rights are reserved by C. KANDEEPAN et al.

Profile of Pharmacologically Active Phyto-Compounds in *Rosmarinus officinalis* L. (Rosemary) Essential Oil



S. AFROZE NAVEED BASHA, C. KANDEEPAN*

PG and Research Department of Zoology, Arulmigu Palaniandavar College of Arts and Culture, Palani -624601, Dindigul District, TamilNadu, India

Submitted: 12 November 2020
Revised: 02 December 2020
Accepted: 22 December 2020





www.ijppr.humanjournals.com

Keywords: Rosmarinus officinalis; Rosemary Essential Oils (REO); Pharmacological Activity; ADMET; Bioactive Compounds; GCMS

ABSTRACT

Plant Based Natural Products (PBNPs) have contributed to the development of many drugs for diverse indications. Worldwide interest in use of plants based natural products (PBNPs) has been growing, and its beneficial effects being rediscovered for the development of new drugs. Literature survey on indigenous traditional knowledge bestows ethnopharmacological potentials of PBNPs, which has inspired current research in drug discovery; PBNPs provide baseline for the development of novel drug leads against various pharmacological targets. Studies report that rosemary essential oil (REO) extracts in particular show biological bioactivities such hepatoprotective, antifungal, insecticide, antioxidant and antibacterial. It is well known that the biological properties in rosemary are mainly due to phenolic compounds. However, their application is limited because of their odor, color and taste. Owing to the widespread applications of phytocompounds in REO - GCMS was performed. GCMS analysis detected 22 compounds of which 6 compounds were in abundant. Their ADMET properties were evaluated to ponder its application.

INTRODUCTION

Rosmarinus officinalis L. (Rosemary) is a medicinal plant native to the Mediterranean region and cultivated around the world (De Oliveira *et al.*, 2019). Besides, therapeutic application, it is commonly used as a condiment and food preservative. *R. officinalis* contains many bioactive molecules, phyto-compounds, endowed with pharmacological activities, such as anti-aging, anti-inflammatory, antioxidant, antimicrobial, antiproliferative, antitumor, tumor-protective, tumor-inhibitory and attenuating activities (Stevanović *et al.*, 2018).

Essential oils (EOs) a major group of phytogenic bioactive compounds (PBAC) have been used for variety of purposes over thousands of years. Due to their strong aromatic properties and bioactive nature, EOs have been used in aromatherapy, as flavor and fragrances in cosmetics, foods, and more recently as pharmaceuticals, natural preservatives, additives, and biopesticides (Al-Shalah *et al.*, 2020). EOs are concentrated form of liquid mixtures of volatile compounds of plant origin with unique structural chemistry including terpenoid and non-terpenoid hydrocarbons and their oxygenated derivatives, with natural color, odor and flavor, or "essence" of their source - volatile/ odoriferous oil. Essential oils are isolated from various plant components such as leaves, fruit, bark, root, wood, heartwood, gum, balsam, berries, seeds, flowers, twigs, and buds (Chávez-González *et al.*, 2016).

Role of PBNPs in drug development has been practiced and well documented since antiquity and recently increasing, not because the bioactive compounds are directly used as therapeutic agents but due to fact that they are used as raw material for drug synthesis, or as a base model for new biologically active compounds due to its GRAS nature. As people are more concerned about the negative effect of synthetic chemicals in food, there is a need to find "GO" products with no or lesser side effects. Therefore, there is a growing interest in using natural extracts as alternatives for synthetic additives because of (a) their synergy with other preservation methods (b) generally regarded as safe, and (c) PBNPs have properties such as antioxidant, antidiabetic, antimutagenic, antitoxigenic and antibacterial. Among the most effective antioxidant constituents of REO, the cyclic diterpene diphenols, carnosolic acid and carnosol have been identified. In addition, REO extract contains carnosic acid, epirosmanol, rosmanol, methylcarnosate and isorosmanol (Bosin *et al.*, 2007). However, validating and using plants as a phytopharmaceutical chemistry requires a great deal of basic and applied research, in order to set this resource at the same level of importance of conventional pharmaceutical products (Atanasov *et al.*, 2015).

Rosmarinus officinalis L. (Rosemary)

Rosmarinus officinalis L., commonly known as rosemary, belongs to the Lamiaceae family. The genus Rosmarinus has been merged into the genus Salvia in a recent phylogenetic analysis. Botanical Description: Plants to 2 m tall. Bark dark grey, irregularly fissured, exfoliating, young branches densely white stellate-tomentulose. Leaves tufted on branches, sessile to short petiolate; leaf blade 1-2.5 cm × 1-2 mm, leathery, adaxially somewhat shiny, sub-glabrous, abaxially densely white stellate-tomentose, base attenuate, margin entire, revolute, apex obtuse. Calyx ca. 4 mm, densely white stellate tomentose and glandular outside, upper lip sub-circular, teeth of lower lip ovate-triangular. Corolla blue-purple, less than 1 cm, sparsely pubescent outside, tube slightly exerted, apex of upper lip 2-lobed, lobes ovate, middle lobe of lower lip constricted at base into claw, lateral lobes oblong. Fl. Nov (Gamble, 1935; Mathews, 1981).

Ethnobotanical perspective: Bioactive molecules have pharmacological activities, such as anti-inflammatory, antioxidant, antimicrobial, antiproliferative, antitumor and protective, inhibitory and attenuating activities with ability to attenuate asthma, atherosclerosis, cataract, renal colic, hepatotoxicity, peptic ulcer, inflammatory diseases, ischemic heart disease, antioxidant and anti-inflammatory actions of rosmarinic acid, control of hypercholesterolemia myocardial blood pressure reduction with rosmarinic acid, antiulcer action, lipid peroxidation reduction in heart and brain, antiangiogenic and neuroprotective effects of carnosic acid and carnosol, prevention of problems related to atherosclerosis, anticancer (Tai et al., 2007) and antiproliferative effects. antiviral and antimicrobial actions. hepatoprotective, nephroprotective and radioprotective capacities.

R. officinalis has been traced for its origin from the Mediterranean region. It is an aromatic plant, a unique spice commercially available for use as an antioxidant. REO extracts have been used in the treatment of diseases, due to its hepatoprotective potential (Rašković et al., 2014), therapeutic potential for Alzheimer's disease (Habtemariam, 2016) and its antiangiogenic effect (Kayashima and Matsubara, 2012). On the other hand, it is used in food preservation, because they prevent oxidation and microbial contamination (Alavi et al., 2020). Therefore, rosemary extract could be useful for replacing or even decreasing synthetic antioxidants in foods. EFSA (European Food Safety Authority) recently, reviewed the safety of rosemary extracts and concluded that there are high-intake estimates ranging from 0.09 (elderly) to 0.81 (children) mg/kg per day.

Systematic Position of *Rosmarinus officinalis* L. (Rosemary)

Class : Equisetopsida

Subclass : Magnoliidae

Superorder : Asteranae

Order : Lamiales

Family : Lamiaceae

Genus : Rosmarinus

Species : officinalis

Common : Rosemary

Habit : Herb

Parts used : Leaf

Ailments : Anti-inflammatory, antioxidant, antimicrobial, antitumor

MATERIALS AND METHODS

Preparation and extraction of sample

Protocol for preparation of sample was according to the methods previously described by Eleyinmi (2007), but with modifications wrt temperature and duration of drying the sample. A 100 g leaf was weighed and dried in an oven at 60°C. Dried sample was ground into powder using Thomas-Willey milling machine and sieved on a wire mesh screen (3 × 3 mm²). Sample was stored at 4°C in air-tight container with screw caps. Sample was prepared according to the methods previously described by Rašković *et al.*, (2015). 25 g of sample was suspended in 250 mL of distilled water in stoppered flasks and allowed to stand for 24hrs, filtered with Whatman No 24 filter paper, concentrated in a rotary evaporator for 12 h at 50°C and dried in vacuum desiccator. Yield was calculated to be 6.06% w/w. Extract was suspended in ethyl acetate and subjected to GC-MS analysis.

GC-MS Analysis

Rosmarinus officinalis L. (Rosemary) Essential Oil was purchased commercially from the local market in Palani, Dindigul District, Tamil Nadu, India. Phyto-components were identified using GC–MS detection system as previously described Rašković *et al.*, (2015) but with minor modification, whereby portion of the extract was analysed directly by headspace sampling. GC–MS analysis was accomplished using an Agilent 7890A GC system set up with 5975C VL MSD (Agilent Technologies, CA, and USA). Capillary column used was DB-5MS (30 m × 0.25 mm, film thickness of 0.25 µm; J&W Scientific, CA, USA). Temperature program was set as follows: initial temperature 50°C held for 1 min, 5°C per min to 100°C, 9°C per min to 200°C held for 7.89 min, and the total run time was 30 min. The flow rate of helium as a carrier gas was 0.811851 mL/min. MS system was performed in electron ionization (EI) mode with Selected Ion Monitoring (SIM). The ion source temperature and quadruple temperature were set at 230°C and 150°C, respectively. Identification of phyto-components was performed by comparison of their retention times and mass with those of authentic standards spectra using computer searches in NIST08.L and Wiley7n.l libraries.

ADMET prediction

Selected phytocompounds were subjected to ADMET prediction using QikProp (version 4.3, Suite 2015-1; Schrödinger, LLC: New York, NY) and toxicity prediction using TOPKAT (Accelrys, Inc., USA). QikProp develops and employs QSAR/QSPR models using partial least squares, principal component analysis and multiple linear regression to predict physic-chemically significant descriptors (Zhou *et al.*, 2020).

RESULTS AND DISCUSSION

GCMS analysis of Rosmarinus officinalis (Rosemary) essential oil

The chemical composition of EOs depends on plant genetics, growth conditions, development stage at harvest, and processes of extracting active compounds. Different parts of the plant (bark, leaf, fruit and seed) have been extensively investigated for their bioactive phytochemical constituents in various plants (Ramya *et al.*, 2012). GC-MS analysis revealed that the extract of *Rosmarinus officinalis* contained different volatile oils. Tricyclo[3.2.1.0(2,4)]octane,8-methylene($1.\alpha.,2.$ $\alpha.,4.\alpha.,$ $5.\alpha.$)- (C₉H₁₂), 3.237, 2 hits;

Benzene, 1-ethyl-2,3-dimethyl- (C₁₀H₁₄), 4.318 min, 10 hits; Cyclohexanemethanol, 4hydroxy- α , α , 4-trimethyl- (C₁₀H₂₀O₂), 4.436 min, 10 hits; Cyclohexanol, 5-methyl-2-(1methylethenyl)- ($C_{10}H_{18}O$), 0.508 min, 10 hits; Eucalyptol ($C_{10}H_{18}O$), 4.566, 6 hits; 1,8-Cineole; 470-82-6; 1,8-Cineol; $(C_{10}H_{18}O)$, 4.655 min, 10 hits; Geranyl tiglate $(C_{15}H_{24}O_2)$, 4.811, 2 hits; 3-Oxatricyclo[4.1.1.0(2,4)]octane, 2,7,7-trimethyl- (C₁₀H₁₆O), 4.885 min, 10 hits; -Naphthalenol, decahydro- (C₁₀H₁₈O), 4.959 min, 10 hits; 4-Cyclooctene-1-methanol (C₉H₁₆O), 5.02 min, 10 hits; 1,2,4,5-Tetrazine (C₂H₂N₄), 5.243 min, 10 hits; 1-Cyclopentene-1-methanol, $.\alpha.,\alpha.,4,5$ tetramethyl-, trans- $(C_{10}H_{18}O),$ 6.045 min, hits; Tricyclo[4.2.2.0(1,5)]dec-7-ene ($C_{10}H_{14}$), 6.159 min, 10 hits; (1S-(1A,2 α , β))-1-isopropenyl-4methyl-1,2-cyclohexanediol ($C_{10}H_{18}O_2$), 6.208 min, 10 hits; Bicyclo[3.1.1]hept-3-en-2-one, 4,6,6-trimethyl-,(1S)- (C₁₀H₁₄O), 6.244 min, 10 hits; Linalyl isobutyrate (C₁₄H₂₄O₂), 6.454 min, 10 hits; Bicyclo[2.2.2]oct-2-ene, 1-methylamino- (C₉H₁₅N), 7.084 min, 10 hits; Benzenemethanol, 4-ethyl- (C₉H₁₂O), 7.092 min, 10 hits; Dicyclopentadiene diepoxide $(C_{10}H_{12}O_2)$, 7.344 min, 10 hits; 1,8-Nonadiyne (C_9H_{12}) , 7.5 min, 10 hits; 2,6,11,15-Tetramethyl-hexadeca-2,6,8,10,14- pentaene (C₂₀H₃₂), 20.122, 2 hits; Phthalic acid, di(6methylhept-2-yl) ester (C₂₄H₃₈O₄), 35.075 min, 10 hits respectively (**Table 1**; **Fig. 1**).

Sienkiewicz *et al.* (2013) reported that rosemary essential oil contains mainly 1,8-cineole (46.4%), camphor (11.4%) and α-pinene (11.0%). The composition of the rosemary essential oil used by Jiang et al. (2011), was composed mainly by 1,8-cineole (26.54%) and α-pinene (20.14%). Bendeddouche *et al.* (2011), observed that the main constituents of the tested essential oil were camphor (37.6%), 1,8-cineole (10.0%), p-cymene-7-ol (7.8%) and borneol (5.4%). Biological activities of these secondary metabolites of *R. officinalis* have been reported for its antitumor, antioxidant, anti-infectious, anti-inflammatory, and analgesic activities and effects on the central nervous system, endocrine system, disorders such as cardiac remodeling after myocardial infarction, body weight changes, dyslipidemia, cerebral ischemia, hepato-nephrotoxicity, stress, and anxiety. Anti-inflammatory activity of rosemary has been attributed to the presence and synergistic activity of carnosol and carnosic, rosmarinic, ursolic, oleanolic, and micromeric acids (Alavi *et al.*, 2020). Specifically, anti-inflammatory activity has been attributed to synergic effects of ursolic and micromeric acids present in REO. These natural drugs can be proposed for preclinical and clinical studies in different diseases and pathological conditions.

CONCLUSION

Rosemary contains a large variety of bioactive molecules with great therapeutic potential such as triterpenes (e.g., ursolic and oleanolic acid), tricyclic diterpenes (e.g., carnosic acid and carnosol), phenolic acids (e.g., caffeic acid and rosmarinic acid), and essential oils. These secondary metabolites have been formulated in topical dosages. REO has anti-inflammatory, antimicrobial and antioxidant properties, which have been extensively reported in oral formulations. However, development of new formulations containing other less common REO extracts is warranted through trials to evaluate and establish the potentials of pharmacologically active phyto-compounds towards safety and efficacy, in treating various pathological conditions.

ACKNOWLEDGEMENT

The author is grateful to the Management, Arulmigu Palaniandavar College of Arts and Culture, Palani - 624601, Dindigul District, Tamil Nadu, India for their support by providing the required facilities to carry out the research work.

REFERENCES

- 1) Alavi MS, Fanoudi S, Ghasemzadeh Rahbardar M, Mehri S, Hosseinzadeh H. An updated review of protective effects of rosemary and its active constituents against natural and chemical toxicities. Phytotherapy Research. 2020 Oct 12.
- 2) Al-Shalah LA, Hindi NK, Mohsen IH. Essential Oils. Essential Oils-Bioactive Compounds, New Perspectives and Applications. 2020.
- 3) Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P, Temml V, Wang L, Schwaiger S, Heiss EH, Rollinger JM, Schuster D, Breuss JM, Bochkov V, Mihovilovic MD, Kopp B, Bauer R, Dirsch VM, Stuppner H. Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnol Adv. 2015; 33(8):1582-1614.
- 4) Bendeddouche M.S., Benhassaini H., Hazem Z., Romane A. Essential oil analysis and antibacterial activity of *Rosmarinus tournefortii* from Algeria. Nat. Prod. Commun. 2011;6:1511–1514.
- 5) Bozin B., Mimica-Dukic N., Samojlik I., Jovin E. Antimicrobial and Antioxidant properties of Rosemary and Sage (*Rosmarinus officinalis* L. and *Salvia officinalis* L., Laminaceae) essential oils. J. Agric. Food Chem. 2007;55:7879–7885.
- 6) Chávez-González ML, Rodríguez-Herrera R, Aguilar CN. Essential oils: A natural alternative to combat antibiotics resistance. Elsevier Academic Press: London Wall, London, UK. 2016:227-37.
- 7) De Oliveira JR, Camargo SE, De Oliveira LD. *Rosmarinus officinalis* L. (rosemary) as therapeutic and prophylactic agent. Journal of Biomedical Science. 2019;26(1):5-23.
- 8) Habtemariam S. The therapeutic potential of rosemary (*Rosmarinus officinalis*) diterpenes for Alzheimer's disease. Evidence-Based Complementary and Alternative Medicine. 2016.
- 9) Jiang Y., Wu N., Fu Y.-J., Wang W., Luo M., Zhao C.J., Zu Y.G., Liu X.L. Chemical composition and antimicrobial activity of the essential oil of Rosemary. Environ. Toxicol. Pharmacol. 2011;32:63–68
- 10) Kayashima T, Matsubara K. Antiangiogenic effect of carnosic acid and carnosol, neuroprotective compounds in rosemary leaves. Bioscience, biotechnology, and biochemistry. 2012:1111292741
- 11) Gamble, J. S. 1935 "The flora of the Presidency of Madras, London: Adlard & Son." Ltd. London.

- 12) Matthew, K. M. 1983 "The Flora of Tamil Nadu Carnatic (The Rapinat Herbarium, St. Joseph" s College, Tiruchirapalli, India)." Vol I-III.Ramya, S., Neethirajan, K., & Jayakumararaj, R. Profile of bioactive compounds in *Syzygium cumini*—a review. Journal of Pharmacy Research, 2012;5(8):4548-4553.
- 13) Rašković A, Milanović I, Pavlović N, Ćebović T, Vukmirović S, Mikov M. Antioxidant activity of rosemary (*Rosmarinus officinalis* L.) essential oil and its hepatoprotective potential. BMC complementary and alternative medicine. 2014;14(1):225.
- 14) Sienkiewicz M., Lysakowska M., Pastuszka M., Bienias W., Kowalczyk E. The potential of use Basil and Rosemary essential oils as effective antibacterial agents. Molecules. 2013;18:9334–9351.
- 15) Stevanović ZD, Bošnjak-Neumüller J, Pajić-Lijaković I, Raj J, Vasiljević M. Essential Oils as Feed Additives-Future Perspectives. Molecules. 2018;23(7):1717.
- 16) Tai J., Cheung S., Wu M., Hasman D. Antiproliferation effect of Rosemary (*Rosmarinus officinalis*) on human ovarian cancer cells *in vitro*. Phytomedicine. 2012;19:436–443.
- 17) Zhou Y, Wu F, Li L, Shen X, Chen G, Wang X, Liang X, Tan M, Huang Z. Computational approaches in preclinical studies on drug discovery and development. Frontiers in Chemistry. 2020;8:726.



Table No. 1: GCMS based list of bioactive compounds in *Rosmarinus officinalis* essential oil

RT	Name of the Compound	Molecular Formula	Hits (DB)	
3.237	Tricyclo[3.2.1.0(2,4)]octane, 8- methylene(1.α.,2.α.,4.α.,5.α.)-	C ₉ H ₁₂	2	
4.318	Benzene, 1-ethyl-2,3-dimethyl-	$C_{10}H_{14}$	10	
4.436	Cyclohexanemethanol, 4-hydroxyα.,α.,4-trimethyl-	$C_{10}H_{20}O_2$	10	
0.508	Cyclohexanol, 5-methyl-2-(1-methylethenyl)-	C ₁₀ H ₁₈ O	10	
4.566	Eucalyptol	C ₁₀ H ₁₈ O	6	
4.655	1,8-Cineole; 470-82-6; 1,8-Cineol;	C ₁₀ H ₁₈ O	10	
4.811	Geranyl tiglate	C ₁₅ H ₂₄ O ₂	2	
4.885	3-Oxatricyclo[4.1.1.0(2,4)]octane, 2,7,7-trimethyl-	C ₁₀ H ₁₆ O	10	
4.959	-Naphthalenol, decahydro-	C ₁₀ H ₁₈ O	10	
5.02	4-Cyclooctene-1-methanol	C ₉ H ₁₆ O	10	
5.243	1,2,4,5-Tetrazine	$C_2H_2N_4$	10	
6.045	1-Cyclopentene-1-methanol, .α.,α.,4,5- tetramethyl-, trans-	$C_{10}H_{18}O$		
6.159	Tricyclo[4.2.2.0(1,5)]dec-7-ene	C ₁₀ H ₁₄	10	
6.208	(1S-(1A,2α,4β))-1-isopropenyl-4- methyl-1,2- cyclohexanediol	C ₁₀ H ₁₈ O ₂	10	
6.244	Bicyclo[3.1.1]hept-3-en-2-one, 4,6,6-trimethyl-,(1S)-	C ₁₀ H ₁₄ O	10	
6.454	Linalyl isobutyrate	C ₁₄ H ₂₄ O ₂	10	
7.084	Bicyclo[2.2.2]oct-2-ene, 1-methylamino-	C ₉ H ₁₅ N	10	
7.092	Benzenemethanol, 4-ethyl-	C ₉ H ₁₂ O	10	
7.344	Dicyclopentadiene diepoxide	$C_{10}H_{12}O_2$	10	
7.5	1,8-Nonadiyne	C ₉ H ₁₂	10	
20.122	2,6,11,15-Tetramethyl-hexadeca-2,6,8,10,14- pentaene	$C_{20}H_{32}$	2	
35.075	Phthalic acid, di(6-methylhept-2-yl) ester	C ₂₄ H ₃₈ O ₄	10	

Table No. 2: Physical and chemical properties of selected bioactive compounds in R. officinalis

Compound/ PubChem CID	IUPAC Name/ Canonical SMILES	2D Chemical Structure	3D Interactive Chemical Structure
3-Ethyl-o-xylene 13621	Benzene, 1-ethyl-2,3-dimethyl CS: CCC1=CC=CC(=C1C)C	H ₃ C CH ₃ CH ₃	THE STATE OF THE S
Terpin 6651	Cyclohexanemethanol, 4-hydroxy-α,α,4- trimethyl CC1(CCC(CC1)C(C)(C)O)O Food additives/ ingredients (flavoring agents) for human consumption	H ₂ C CH ₃	A A A A A A A A A A A A A A A A A A A
Isopulegol 15730758	Cyclohexanol, 5-methyl-2-(1-methylethenyl)-) CC1CCC(C(C1)O)C(=C)C		Here
Eucalyptol 73918	1,8-Cineole; 470-82-6; 1,8-Cineol CC1(C2CCC(O1)(CC2)C)C	CH ₃ O CH ₃	
α-Pinene oxide 91508	3-Oxatricyclo[4.1.1.0(2,4)]octane, 2,7,7-trimethyl- CC1(C2CC1C3(C(C2)O3)C)C	H ₃ C CH ₃	
2-Naphthalenol, decahydro- 13216	Naphthalenol, decahydro- C1CCC2CC(CCC2C1)O	OH H OH	THE STATE OF THE S

Table No. 3: Molecular and biological properties of selected bioactive compounds in R. officinalis

CID	13621	6651	15730758	73918	91508	13216
MF	C ₁₀ H ₁₄	$C_{10}H_{20}O_2$	C ₁₀ H ₁₈ O	C ₁₀ H ₁₈ O	C ₁₀ H ₁₆ O	C ₁₀ H ₁₈ O
miLogP	3.65	1.61	2.65	2.72	2.74	2.50
MW (g/mol)	134.22	172.26	246.4	154.25	152.23	154.25
TPSA	0.00	40.46	20.23	9.23	12.53	20.23
natoms	10	12	11	11	11	11
nON	0	2	1	1	1	1
nOHNH	0	2	1	0	0	1
nviolations	0	0	0	0	0	0
nrotb	1	1	1	0	0	0
volume	150.53	184.55	171.55	166.66	155.87	167.06
GPCR ligand	- 1.11	- 0.39	- 0.78	- 0.93	- 0.40	- 0.49
Ion channel modulator	- 0.81	0.35	- 0.16	- 0.01	- 0.41	- 0.09
Kinase inhibitor	- 1.41	- 1.12	- 1.59	- 1.60	- 1.24	- 0.98
Nuclear receptor ligand	- 1.23	- 0.35	- 0.22	- 1.07	- 0.17	- 0.48
Protease inhibitor	- 1.47	- 0.55	- 0.71	- 0.90	0.15	- 0.40
Enzyme inhibitor	- 0.77	- 0.02	- 0.14	- 0.15	0.34	- 0.02

Table No. 4: Summary of toxicity risk of compounds towards drugability/ drug score

Compound	Mutagenic	Tumorigenic	Irritant	RE	DL	DS
3-Ethyl-o-xylene	None	None	High	None	-1.94	0.30
Terpin	None	None	None	None	-0.61	0.84
Isopulegol	None	None	None	None	-21.93	0.46
Eucalyptol	High	None	None	High	-3.17	0.17
α-Pinene oxide	High	None	High	None	-1.28	0.21
2-Naphthalenol, decahydro-	None	None	High	None	-5.07	0.28